In his weekly clinical update, Daniel Griffin and Vincent Racaniello discuss their continuing struggle to understand the ongoing outbreak of cyclospora, decimation of US public health including 30% or greater loss of personnel from the CDC, continuing measles outbreaks here and aboard, a mumps outbreak in San Diego and a Hib death in Montana, criminalization of pediatricians in Texas, dengue associated death in Florida, Ebola in Kenya, a new Legionnaires outbreak, screw worm cases, and a hearing in Florida to end requirements of four vaccines including Hib and chickenpox, before Dr. Griffin deep dives into recent statistics RSV, influenza, SARS-CoV-2 infections, the continued measles outbreak in Pennsylvania, US, Canada, statistics on vaccine preventable disease mortality in children, effectiveness of adjuvanted high dose influenza vaccine and contacting your federal government representative to stop the assault on science and biomedical research.
Small quantity lipid-based nutritional supplementation and measles vaccination coverage in children aged 6−23 months: a pragmatic cluster-randomized trial (Nature Medicine)
Measles Outbreak in Amish Country Forces Some to Rethink Vaccines (NY Times)
Annual flu vaccines are far from ideal — this is why (Nature)
Virology's most wanted: the influenza virus (Nature)
Early flu spike closes schools, clinics move up vaccinations (The Asahi Shimbun)
Flu season could kick off 'incredibly' early — what scientists are watching (Nature)
Near real-time data on the human neutralizing antibody landscape to influenza virus as of the summer of 2026 to inform vaccine-strain selection (Summary results)(Jbloomlab)
Influenza: Waste water scan for 11 pathogens (WastewaterSCan)
US respiratory virus activity (CDC Respiratory Illnesses)
Vaccine-Preventable Infectious Disease Mortality Among Children in the Post-vaccine Era: Persistent Burden and Emerging Temporal Trends (Cureus Journal of Medical Science)
Flu vaccine recommendations: Vaccines and Related Biological Products Advisory Committee March 12, 2026 Meeting Announcement (FDA)
Adjuvanted and high-dose influenza vaccines had comparable effectiveness against test-confirmed influenza outcomes including hospitalizations in overall and high-risk older adults in the 2022–2023 and 2023–2024 seasons (International Journal of Infectious Diseases)
Influenza vaccine effectiveness against influenza A-associated hospitalization and severe in-hospital outcomes among adults in the United States, 2024–2025 (CID)
RSV: Waste water scan for 11 pathogens (WastewaterSCan)
Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines (Moderna)
Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season (novavax)
Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine (Pfizer)
Temporary Cessation of DMARD Therapy and COVID-19 Supplemental Dose Vaccine Immunogenicity in Patients With Inflammatory Arthritis (JAMA Internal Medicine)
Podden och tillhörande omslagsbild på den här sidan tillhör
Vincent Racaniello. Innehållet i podden är skapat av Vincent Racaniello och inte av,
eller tillsammans med, Poddtoppen.
